Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 February 2024 | Story Lacea Loader | Photo SUPPLIED
Prof Prince Ngobeni
Prof Prince Ngobeni, newly appointed Campus Principal of the UFS Qwaqwa Campus.

The University of the Free State (UFS) has appointed Prof Prince Ngobeni as Principal of the Qwaqwa Campus as from 1 February 2024.

Prof Ngobeni completed his first qualification in Analytical Chemistry at the then Technikon North-West before furthering his studies at the then Technikon Pretoria. He completed a DTech in Chemistry at the Tshwane University of Technology (TUT) in 2003. In 2016, he enrolled for a Doctor of Business Administration in Higher Education at the University of Bath in England. 

His lecturing career began at TUT in 1995 where he progressed from Head of Department: Chemistry in 2003 to Associate Dean: Faculty of Science in 2010, before being appointed as Executive Dean of the Faculty of Sciences at TUT in 2015 – a position he held until 2023. He also served as Interim Campus Rector of TUT’s Pretoria Campus from 2018 to 2020.

“With extensive years of academic leadership experience, Prof Ngobeni has the experience required to guide the Qwaqwa Campus towards the university’s Vision 130. The campus is already recognised as a leader in some of its unique research fields, and Prof Ngobeni’s strong research background will be valuable in this regard,” says Prof Francis Petersen, Vice-Chancellor and Principal of the UFS. 

Prof Ngobeni is a member of several professional bodies in his field of expertise, including MatTEK at the Council for Scientific and Industrial Research (CSIR), the South African Chemical Institute (SACI), the Society for Atomic Spectroscopy, and the South African Council for Natural Scientific Professions (SACNASP). During his career, he has also secured research funding for individual projects and international partnerships. Prof Ngobeni also initiated chemistry practical sessions for local schools and participated in the Technology Station in Chemicals project, which offers a wide range of services designed to assist small and medium enterprises (SMEs) in the chemical sector.

His substantial list of publications in journals and books covers a range of chemistry-related and managerial topics. He is also a well-versed presenter at local and international conferences. 

“The Qwaqwa Campus has experienced major developments in recent years; I look forward to further contributing to the growth of the campus and to support the university in achieving its Vision 130,” says Prof Ngobeni. 

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept